Phase II Study of Bevacizumab, Cisplatin, and Docetaxel Plus Maintenance Bevacizumab as First-Line Treatment for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer Combined With Exploratory Analysis of Circulating Endothelial Cells: Thoracic Oncology Research Group (TORG)1016

BMC Cancer - United Kingdom
doi 10.1186/s12885-018-4150-y

Related search